About Viatris
Viatris news and updates
Biocon Ltd partnered with Viatris Inc on Feb 28th 22'.
Today's slump comes after the company announced that its subsidiary Biocon Biologics had entered into a definitive agreement with Viatris to acquire the US-based company's biosimilars business and the deal is worth up to $3.335 billion in stock and cash.
Jan 1, 2022 | cnbctv18.comViatris Inc sold assets to Biocon Ltd in the amount of $3.3B on Feb 28th 22'.
Accordingly, Biocon Biologics Ltd. (BBL) will acquire Viatris’ biosimilars business to create a unique fully integrated global biosimilars enterprise.
Jan 1, 2022 | diwou.comViatris Inc decreases headcount by 75
Viatris notified the state in October that it planned to close the site and lay off 75 workers effective Jan. 7, pharmaceutical news site FiercePharma said.
Jan 1, 2022 | therealdeal.comViatris Inc partners with Health
Thus, to help address these emerging social and emotional needs in Filipino households, healthcare company Viatris in partnership with the Department of Health (DOH) have made educational parenting videos from Sesame Workshop available online through the DOH official Facebook page ( www.facebook.com/OfficialDOHGov ) as well as the Healthy Pilipinas campaign page ( www.facebook.com/DOHHealthyPilipinas ).
Jan 1, 2022 | inquirer.netViatris Inc decreased headcount by 1500 on Dec 1st 20'.
In December 2020, Viatris announced that they planned to shut down the plant, cutting 1,500 jobs in the process.
Jan 1, 2022 | wv.govViatris Inc partnered with West Virginia University on Mar 31st 21'.
Viatris, formerly known as Mylan Pharmaceuticals, has announced it is planning on entering into a memorandum of understanding with West Virginia University regarding the potential transfer of ownership of the Chestnut Ridge facility in Morgantown.
Jan 1, 2021 | wvpublic.orgViatris Inc partners with Kindeva
Viatris Inc. announces receipt of the first FDA approval for generic version of Symbicort ® inhalation aerosol, Breyna™ (budesonide and formoterol fumarate dihydrate inhalation aerosol), in partnership with Kindeva.
Jan 1, 2022 | empr.comBiocon Ltd acquired Viatris Inc for $3.3B on Feb 1st 22'.
Biocon has agreed to purchase the biosimilars business of its fellow copycat medicines maker Viatris, announcing Monday a cash-and-stock deal worth up to $3.3 billion.
Jan 1, 2022 | biopharmadive.comViatris Inc launches Breyna generic version of AstraZeneca’s Symbicort
You may also be interested in... Facing down a key patent infringement trial beginning on 19 May, Viatris is continuing to eye an opportunity to launch its Breyna generic version of AstraZeneca’s Symbicort before patent expiry in 2023.
Jan 1, 2022 | informa.comViatris Inc launched Abevmy on May 12th 22'.
Viatris Inc. announced that Abevmy® is now available in Canada.
Jan 1, 2022 | capho.orgViatris Inc launches cancer drug bevacizumab
Bengaluru: Biocon Biologics and Viatris (formerly Mylan) have launched cancer drug bevacizumab under the brand name Abevmy in Canada.
Jan 1, 2022 | indiatimes.comViatris Inc launches Abevmy in Canada
Biocon : The company's subsidiary Biocon Biologics and Viatris launched Abevmy (bBevacizumab) in Canada.
Jan 1, 2022 | business-standard.comViatris Inc launches Abevmy in Canada, a biosimilar product for treating cancer
Viatris and Biocon have introduced their Abevmy biosimilar bevacizumab version of Avastin in Canada.
Jan 1, 2022 | informa.comViatris Inc launched Hulio on Feb 1st 21'.
In addition to the therapeutic area of oncology, Viatris Canada launched Hulio (adalimumab) in February 2021 for chronic inflammatory conditions.
Jan 1, 2022 | viatris.comViatris Inc launches US generic version of Nexavar
Viatris and Natco have introduced the first US generic version of Nexavar, with the exclusive launch expected to further boost India’s Natco after a healthy financial fourth quarter that was bolstered by revenues from the firm’s recent launch of a Revlimid rival with Teva.
Jan 1, 2022 | informa.comViatris Inc closes offices in Morgantown, West Virginia, United States
In December 2020 Viatris had announced plans to close the Morgantown Mylan Chestnut Ridge oral solid dose manufacturing facility on July 31, 2021, eliminating 1,500 jobs.
Jan 1, 2022 | wvnews.comViatris Inc is developing biosimilar to BOTOX
Revance has also partnered with Viatris Inc. to develop a biosimilar to BOTOX®, which would compete in the existing short-acting neuromodulator marketplace.
Sep 11, 2022 | otcdynamics.comViatris Inc partners with International Alliance of Patients' Organizations
To help people take an active role in their health and create better outcomes, Viatris has partnered with the International Alliance of Patients’ Organizations (IAPO), which promotes patient-centered healthcare worldwide, to create Patient Academy.
Aug 31, 2022 | viatris.comViatris Inc had issues with patent infringement case on Sep 23rd 22'.
On Friday, Merck announced positive results on its patent infringement case against Viatris, while Amgen faces political headwinds from the White House.
Sep 23, 2022 | biospace.comViatris Inc launched Tecfidera copycat on Jan 1st 20'.
However, in 2020, another biotech called Viatris Inc. launched a generic Tecfidera copycat.
Oct 6, 2022 | bizjournals.comViatris Inc recognized as World's Best Employers 2022 on Oct 11th 22'.
Viatris Inc. (NASDAQ: VTRS), a global pharmaceutical company, today announced that it has been named to Forbes' list of World's Best Employers 2022.
Oct 11, 2022 | marketscreener.comViatris Inc is developing biosimilar to BOTOX
Revance has also partnered with Viatris Inc. to develop a biosimilar to BOTOX®, which will compete in the existing short-acting neuromodulator marketplace.
Oct 17, 2022 | biospace.comViatris Inc recognized as winner in three categories at 10th annual LMG Life Sciences 2022 Americas Awards on Nov 18th 22'.
Viatris Inc. (NASDAQ: VTRS ), a global healthcare company, today announced that it has been named the winner in three categories at the 10th annual LMG Life Sciences 2022 Americas Awards, highlighting companies, law firms and legal practitioners behind the most innovative and challenging life science work in the regulatory, corporate, intellectual property and litigation areas.
Nov 18, 2022 | prnewswire.comViatris Inc recognized as Top 25 dividend stock
Viatris Inc (Symbol: VTRS) has been named as a Top 25 dividend stock, according the most recent Dividend Channel ''DividendRank'' report.
Nov 10, 2022 | nasdaq.comViatris Inc hires Sanjeev Narula as CFO
Mylan N.V.and Pfizer announced the appointment of Sanjeev Narula as CFO of Viatris.
Nov 17, 2022 | hrnxt.comViatris Inc launches PRECISION-Renal study
Viatris unveiled the result of its PRECISION-Renal study that compared the kidney incidence and cardiovascular safety among celecoxib (Celebrex Cap.)
Nov 24, 2022 | koreabiomed.comViatris Inc launched Semglee on Nov 1st 21'.
• In November 2021, Biocon and Viatris launched an interchangeable insulin biosimilar named Semglee which is a substitute for Sanofi's diabetes drug Lantus.
Nov 15, 2022 | openpr.comViatris Inc sold assets to Biocon Biologics Ltd. in the amount of $3.34B on Feb 1st 22'.
Biocon in February announced the $3.34 billion cash and equity deal to acquire global biosimilar business of Viatris.
Nov 29, 2022 | indiatimes.comBiocon Biologics Ltd. partnered with Viatris Inc on Feb 1st 22'.
Biocon Biologics Ltd., a subsidiary of Biocon Ltd., announced that it has entered into a definitive agreement with its partner Viatris Inc.
Nov 29, 2022 | hrnxt.comViatris Inc is developing biosimilar to BOTOX
Revance has also partnered with Viatris Inc. to develop a biosimilar to BOTOX®, which will compete in the existing short-acting neuromodulator marketplace.
Nov 21, 2022 | marketscreener.comViatris Inc launched interchangeable biosimilars SEMGLEE injection on Nov 1st 22'.
In November 2022, Viatris Inc. and Biocon Biologics Ltd. announced the U.S. launch of interchangeable biosimilars SEMGLEE (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) injection, an unbranded product, to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes.
Dec 20, 2022 | southwestdailynews.comViatris Inc hired Scott A. Smith as board of directors on Dec 29th 22'.
Viatris Inc. (NASDAQ: VTRS ), a global healthcare company, today announced that Scott A. Smith and Elisha W. Finney have been appointed as Viatris' newest members of its board of directors.
Dec 29, 2022 | prnewswire.com